AIM ImmunoTech Inc. (AIM) Stock

AIM ImmunoTech Inc., an immuno-pharma company based in the United States, specializes in the research and development of innovative therapeutics targeting various cancers, viral diseases, and immune-deficiency disorders. Central to its portfolio is Ampligen, a macromolecular RNA-based drug designed initially for chronic fatigue syndrome (CFS). The company is actively expanding Ampligen's applications to include treatments for renal cell carcinoma, malignant melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.

In addition to Ampligen, AIM ImmunoTech offers Alferon N Injection, an injectable formulation of natural alpha interferon used in the treatment of genital warts, a sexually transmitted disease. The company collaborates extensively through agreements with UMN Pharma Inc., Japanese National Institute of Infectious Diseases, Shionogi & Co., Ltd., Polysciences Inc., and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente, enhancing its research capabilities and strategic partnerships.

Founded in 1966 and headquartered in Ocala, Florida, AIM ImmunoTech Inc. (formerly known as Hemispherx Biopharma, Inc.) has a rich history of pioneering advancements in immunotherapy. With a focus on leveraging RNA-based technologies to combat complex diseases, the company remains committed to advancing novel treatments that address significant unmet medical needs globally.